Business
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse eventsOP-3136 shows evidence of anti-tumor activity across multiple solid tumor typesData support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceuti
About this update from Olema Pharmaceuticals, Inc.
[{"type":"image","alt":"Olema Oncology","displaySize":"","headline":null,"caption":"Olema Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8WMDEniZEx5HC3l8.Api5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122","width":300,"height":86},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8WMDEniZEx5HC3l8.Api5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant","length":124,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":347,"olType":false},{"type":"text","content":"SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data will be presented in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois. Olema will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.","length":835,"tagName":"p"},{"type":"text","content":"“We are pleased to share the initial Phase 1 data for OP-3136, which demonstrated acceptable tolerability and pr...